Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An international, open label, adaptive randomized-controlled platform trial trial of Crizanlizumab in patients hospitalized for COVID-19

Next Previous
Trial Profile

An international, open label, adaptive randomized-controlled platform trial trial of Crizanlizumab in patients hospitalized for COVID-19

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crizanlizumab (Primary)
  • Indications Myelofibrosis; Priapism; Vascular disorders; Vaso-occlusive crisis
  • Focus Therapeutic Use

Most Recent Events

  • 28 Jun 2023 New trial record
  • 25 Jun 2023 Primary endpoint (Organ support-free days, evaluated on an ordinal scale consisting of the number of days alive free of organ support through the first 21 days after trial entry) has not been met, as per results published in the Circulation.
  • 25 Jun 2023 Results published in the Circulation

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top